Stereotactic body radiotherapy (SBRT) is an emerging standard of care for prostate cancer. Over the past few years, there has been a wealth of evidence generated supporting the use of SBRT for prostate cancer, as well as data pertaining to optimal dose, fractionation, and motion management strategies. In this talk, we will review prospective evidence pertaining to these aspects of prostate SBRT and discuss future directions.
Menu
Menu